Hear Dr. Ed LeCluyse from LifeNet Health LifeSciences describe the importance of using data to identify the right hepatocyte lots for your specific applications and provides insight on emerging trends in hepatocyte characterization.

Dr. Ed LeCluyse describes the convenient all-human hepatocyte tri-culture model, highlighting improvements in hepatocyte performance compared to traditional monoculture.

Dr. Chad Deisenroth from the U.S. Environmental Protection Agency Center for Computational Toxicology and Exposure presents a novel in vitro 3D human thyroid microtissue model as a new approach for candidate screening that holds both phenotypic and regulatory relevance.

Learn about the role liver non-parenchymal cells (NPCs) play in NASH and liver fibrosis, liver toxicity and drug-induced liver injury (DILI), and how high-quality NPCs are necessary for recapitulating in vivo cell-cell interactions.

Only LifeNet Health LifeSciences controls every step of every tissues journey from donor to lab while serving researchers needs from early-stage discovery to pre-clinical drug-safety evaluation.

Dr. Chris Willey of University of Alabama at Birmingham’s Departments of Radiation Oncology shares how 3D human microtumors are being established as a human-based diagnostic screening method to optimize chemotherapeutic regimens.

Join us as Dr. Ed LeCluyse reveals how primary human hepatocytes can:

• Fast forward your target identification
• Be applied in drug metabolism and pharmacokinetics
• Improve high content screening

Dr. Mary Jane Cunningham explains how genotyping of primary human hepatocytes may be essential to your experimental design and how knowing the donor’s genotype could help with stratifying hepatocyte lots used in drug discovery and development assays.  

• Learn the basics of genotyping and pharmacogenetics 

• Discover how genotypes relate to the metabolism of Cytochrome P450 isozymes and Phase II molecules 

• Explore how genotypes for these enzymes can be used in experimental design planning

Join us as guest speaker, Dr. Alan Grodzinsky, Professor of Biology, Electrical, and Mechanical Engineering at Massachusetts Institute of Technology, shares exciting details of his research on osteoarthritis on Earth and in space. 

The Genotyping-Tissue Expression Project (GTEx) launched in 2010 by the National Institutes of Health and included the characterization of genetic associations across 49 tissues from over 800 postmortem donors. Laura Siminoff, PhD, Dean at the College of Public Health at Temple University, was a key contributor in GTEx, where she evaluated best practices for communicating and obtaining authorization from donor families.

Join us as Dr. Siminoff describes:

• Recommendations vs. requirements for authorizing tissue donation
• Essential communication when obtaining consent from donor families
• How tissue donation and research authorization was used for the GTEx project

Dr. Jessica Weaver, Research and Product Development Scientist at LifeNet Health, will reveal the latest development with our all-human hepatic Tri-Culture system.  

Key features of the model that will be explored:

• Resemblance to native, human liver architecture
• Maintenance of hepatocyte phenotype and functionality for at least 2 weeks
• New 96-well compatible design amenable to high-throughput screening and robotics applications

Join LifeNet Health R&D Scientist Eda Rogers, PhD as she shares details of how she and other LifeNet Health LifeSciences scientists have isolated, cryopreserved, and characterized primary human thyrocytes. 

Our study shows that these cells:

• Consistently formed 3D thyroid microtissues
• Retained thyroid specific protein expression
• Could represent a valuable tool for evaluating thyroid disruption

Dr. Scott Jewel and Dr. Galen Hostetter, both of the Van Andel Research Institute, will share their best practices for the management and use of biospecimens, specifically around the identification of variables on biospecimen quality and processing that can directly impact research results. 

• Discover how specimens are managed to maintain biospecimen integrity and quality
• Learn how tumor and non-tumor regions can be isolated and analyzed
• Explore alternative procedures used to enrich for target nucleic acid isolation

Ed LeCluyse, PhD., describes how liver non-parenchymal cells (NPCs), including stellate, Kupffer, and liver endothelial cells, play a roll in the progression of liver toxicity and disease. 

• Discover how these human NPCs "role play" with human hepatocytes in the onset and progression of NASH and liver fibrosis
• Learn how high-quality and well-characterized human NPCs are necessary to have an accurate in vitro picture of cell-cell interactions
• Explore how NPCs "act" in liver toxicity and Drug-Induced Liver Injury (DILI)